Prevent Defense
Big news from the HIV prevention community! The AIDS Vaccine Advocacy Coalition (AVAC) is very committed to this cause - as you might be able to guess from their name - but have yet to demonstrate any real success (they supported the failed microbicide trials in South Africa last year) . There are a few phase II clinical trials of HIV vaccines taking place in different parts of Sub-Saharan Africa; I imagine this money from Bill and Melinda will help to finance strategic scale-up and distribution of the drug if the studies prove to be successful. Unfortunately, the studies won't be completed until at least 2008 or 2009. Here's to hoping it all works out!
from The Lancet Blog:
US$14 million grant for HIV prevention campaign
Thursday August 23rd 2007The AIDS Vaccine Advocacy Coalition is launching a new organization to promote the development of a wide variety of HIV prevention strategies, including microbicides and oral preventive drugs.
The launch of the new organization, called The HIV Prevention Research Advocacy Network, was announced by AVAC Tuesdsy, Aug 21 in Seattle at the AIDS Vaccine 2007 conference.
The initiative will be funded by five-year, US$14 million grant from the Bill & Melinda Gates Foundation
According to the press release announcing the network’s launch, the organization will:
•Develop international advocacy partnerships that support both the needs of communities involved in research and a global advocacy movement for HIV prevention research.
• Translate complex scientific ideas to communities AND translate community needs and perceptions to the scientific community.
• Work to hold both research agencies and advocates accountable for accelerating ethical prevention research and development.
• Help ensure that communities, policymakers, and civil society have realistic expectations about HIV prevention research and specific clinical trials.
• Work closely with other groups conducting HIV prevention research advocacy, including microbicide advocacy groups.
AVAC also released it annual report, which provides an overview of the state of HIV vaccine research today. Of particular interest is a section that looks at the slow uptake of both male circumcision as an HIV prevention strategy and the vaccine for human papilloma Virus (HPV). These case studies, the report argues, holds lessons for those seeking to implement other prevention strategies.
To visit AVAC site and download the new report go to: http://www.avac.org/
To visit the AIDS Vaccine 2007 conference website go to: www.hivvaccineenterprise.org/conference/index.html












